Dublin, Nov. 02, 2023 (GLOBE NEWSWIRE) -- The "Global CD3 Antibodies Market, Dosage, Price, Sales & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering. The global ...
NANJING, China, April 15, 2025 /PRNewswire/ -- ProBio, a global leader in the antibody discovery and development, is pleased to announce its upcoming poster presentation at the American Association ...
SHANGHAI--(BUSINESS WIRE)--ITabMed Ltd., a clinical-stage biotech company in China, announced the IND approval from China National Medical Products Administration (NMPA) for A-337, a CD3-activating bi ...
BOSTON, April 01, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 ...
CD3e molecule, epsilon (CD3E), is a single-pass type I membrane glycoprotein found on T cells. It contains one Ig-like (immunoglobulin-like) domain and one ITAM domain. CD3E, along with CD3-gamma, CD3 ...
A phase 1 trial of a human thymus-expressed apoptosis factor in patients with advanced solid tumors: Interim report. This is an ASCO Meeting Abstract from the 2015 ASCO Annual Meeting I. This abstract ...
Cytokine release syndrome (CRS), all grades, is observed in approximately 55%-80% of the patients with relapsed or refractory multiple myeloma and 45%-65% of the patients with B-cell non-Hodgkin ...
Merck & Co. Inc. is acquiring Curon Biopharmaceutical Ltd.’s bispecific antibody CN-201 that targets CD3 and CD19 for B-cell associated diseases, for up to $1.3 billion. Under the terms of the deal, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results